EHResearcher profile · from public sources
Erika P Hamilton
Targets
Filled chips are declared by the researcher; the others come from publications (number of works).
Now
Trials, publications and grants since Nov 2024.
Publication
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.
Annals of oncology : official journal of the European Society for Medical Oncology, Oct 2026
Publication
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.
Clinical cancer research : an official journal of the American Association for Cancer Research, Aug 2026
Publication
Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.
ESMO open, May 2026
Publication
DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, Mar 2026
Publication
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, Jan 2026
Publication
Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, Jan 2026
Publication
ER degradation for ER+/HER2- advanced or metastatic breast cancer: a phase 1 trial.
Nature communications, Dec 2025
Publication
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Dec 2025
Publication
First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, Jul 2025
Publication
Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial.
Nature communications, May 2025
Publication
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
Nature medicine, Jan 2025
Publication
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Clinical cancer research : an official journal of the American Association for Cancer Research, Dec 2024
Co-authors
Who links you
Enter another researcher's profile link or ID to see who has published with both of you.
Is this you? Request a correction or removal: support@frontlightresearch.com
Report an error